References
- Finnegan D PJ, Kettle P, Drake M, Matthews C, Alexander H D, Popat R, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006; 47: 1670–1673
- Richardson P G, Mitsiades C S, Hideshima T, Anderson K C. Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 619–634
- Catley L, Tai Y T, Chauhan D, Anderson K C. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat 2005; 8: 205–218
- Barlogie B, Smith L, Alexanian R. Effective treatment of advanced myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356
- Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006; 20: 1341–1352
- Hideshima T, Richardson P, Chauhan D, Palombella V J, Elliott P J, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076
- Mitsiades N, Mitsiades C S, Richardson P G, Poulaki V, Tai Y T, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380
- Oakervee H E, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762
- Jimenez-Zepeda V H, Dominguez V J. Plasma cell leukemia: a rare condition. Ann Hematol 2006; 85: 263–267
- Gertz M A. Managing plasma cell leukemia. Leuk Lymphoma 2007; 48: 5–6
- Petrucci M T, Martini V, Levi A, Gallucci C, Palumbo G, Del Bianco P, et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma 2007; 48: 180–182
- Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutierrez N, Blade J, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665–667
- Jaskiewicz A D, Herrington J D, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005; 25: 1820–1825
- Grassinger J, Sudhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006; 85: 132–133
- Ataergin S, Arpaci F, Kaya A, Cetin T, Gunhan O. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol 2006; 81: 987–988